Literature DB >> 26865586

Relation of Plasma Fibrinogen Level With the Presence, Severity, and Complexity of Coronary Artery Disease.

Mehmet Mustafa Tabakcı1, Fethullah Gerin2, Murat Sunbul3, Cuneyt Toprak1, Halil İbrahim Durmuş4, Serdar Demir1, Uğur Arslantaş1, Sinan Cerşit1, Ulaankhuu Batgerel1, Ramazan Kargın1.   

Abstract

BACKGROUND: Relation of plasma fibrinogen levels with extent, severity, and complexity of coronary artery disease (CAD) in patients with stable angina pectoris (SAP) has not been adequately investigated. The aim of this study was to evaluate whether plasma fibrinogen level is associated with coronary complexity, severity, and extent assessed by SYNTAX (Synergy between percutaneous coronary intervention with TAXUS and Cardiac Surgery) score (SS).
METHODS: We enrolled 134 consecutive patients with SAP who underwent coronary angiography. Baseline serum fibrinogen levels were measured, and SS was calculated from the study population. The patients were classified into 3 groups by tertiles of SS (SS, control group = 0; intermediate group < 22; and high group ≥ 22).
RESULTS: Plasma fibrinogen levels demonstrated a stepwise increase from control group to high SS group. There was a strong correlation between fibrinogen and the SS ( r = .535, P < .001). Area under the receivers operating characteristic curve of fibrinogen was 0.72 (95% confidence interval [CI] 0.61-0.82; < .001) for predicting a high SS. Fibrinogen value higher than 411 mg/dL has a sensitivity of 75% and a specificity of 64% in prediction of high SS. In multivariate analyses, plasma fibrinogen was observed to be an independent predictor for high SS in patients with stable CAD (odds ratio [OR] 1.01; 95% CI, 1.01-1.02; P < .001).
CONCLUSION: Plasma fibrinogen is a readily measurable systemic inflammatory marker and is independently associated coronary severity and complexity in patients with CAD.

Entities:  

Keywords:  angina pectoris; coronary; fibrinogen; syntax score

Mesh:

Substances:

Year:  2016        PMID: 26865586     DOI: 10.1177/1076029616629210

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  9 in total

1.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

2.  Sex-related differences in the association between plasma fibrinogen and non-calcified or mixed coronary atherosclerotic plaques.

Authors:  Tiewei Li; Fang Wang; Rui Peng; Shengqiang Pei; Zhihui Hou; Bin Lu; Xiangfeng Cong; Xi Chen
Journal:  Biol Sex Differ       Date:  2018-12-05       Impact factor: 5.027

3.  New Insights into the Association between Fibrinogen and Coronary Atherosclerotic Plaque Vulnerability: An Intravascular Optical Coherence Tomography Study.

Authors:  Jun Wang; Lu Jia; Xing Li; Siyu Jin; Xiaomei Li; Fen Liu; Chunfang Shan; Yu Zhang; Yining Yang
Journal:  Cardiovasc Ther       Date:  2019-04-02       Impact factor: 3.023

4.  Relationship Between the Reciprocal Change in Inflammation-Related Biomarkers (Fibrinogen-to-Albumin and hsCRP-to-Albumin Ratios) and the Presence and Severity of Coronary Slow Flow.

Authors:  Osman Kayapinar; Cem Ozde; Adnan Kaya
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

Review 5.  Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches.

Authors:  Diana Jhoseline Medina-Leyte; Oscar Zepeda-García; Mayra Domínguez-Pérez; Antonia González-Garrido; Teresa Villarreal-Molina; Leonor Jacobo-Albavera
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 6.  Fibrinogen and Atherosclerotic Cardiovascular Diseases-Review of the Literature and Clinical Studies.

Authors:  Stanisław Surma; Maciej Banach
Journal:  Int J Mol Sci       Date:  2021-12-24       Impact factor: 5.923

7.  Association between fibrinogen level and the severity of coronary stenosis in 418 male patients with myocardial infarction younger than 35 years old.

Authors:  Xiong-Yi Gao; Bing-Yang Zhou; Min-Zhou Zhang; Xi Zhao; Ping Qing; Cheng-Gang Zhu; Na-Qiong Wu; Yuan-Lin Guo; Ying Gao; Xiao-Lin Li; Yao Wang; Geng Liu; Qian Dong; Li-Heng Guo; Jian-Jun Li
Journal:  Oncotarget       Date:  2017-06-20

8.  Evaluation of lipoprotein-associated phospholipase A2, serum amyloid A, and fibrinogen as diagnostic biomarkers for patients with acute cerebral infarction.

Authors:  Liang Tao; Wang ShiChuan; Zhang DeTai; Hu Lihua
Journal:  J Clin Lab Anal       Date:  2019-11-11       Impact factor: 2.352

9.  Association between fibrinogen-to-albumin ratio and the presence and severity of coronary artery disease in patients with acute coronary syndrome.

Authors:  Zhenzhen Duan; Chaodi Luo; Bowen Fu; Dan Han
Journal:  BMC Cardiovasc Disord       Date:  2021-12-07       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.